guselkumab


( Last Updated : September 2, 2022)
Generic Name:
guselkumab
Project Status:
Active
Therapeutic Area:
Psoriatic arthritis
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Tremfya
Project Line:
Reimbursement Review
Project Number:
SR0733-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active psoriatic arthritis.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
For the treatment of adult patients with active psoriatic arthritis.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open01-Apr-22
Call for patient/clinician input closed30-May-22
Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance, Arthritis Society & CreakyJoints, Canadian Association of Psoriasis Patients (CAPP) and Canadian Psoriasis Network (CPN)

Submission received02-May-22
Submission accepted16-May-22
Review initiated17-May-22
Draft CADTH review report(s) provided to sponsor for comment09-Aug-22
Deadline for sponsors comments18-Aug-22
CADTH review report(s) and responses to comments provided to sponsor16-Sep-22
Expert committee meeting (initial)28-Sep-22
Draft recommendation issued to sponsorOctober 11, 2022
To
October 13, 2022
Draft recommendation posted for stakeholder feedback20-Oct-22
End of feedback period03-Nov-22